Naccarelli 1996.

Methods	RCT Open‐label Loss to follow‐up reported: yes
Participants	Any documented symptomatic AF. Type: paroxysmal 74%, persistent 26% (mean duration: 36 months). n = 239 Men: 38 Age (mean): 58 years Structural heart disease: 83%. LAD: NS. LVEF: NS
Interventions	Flecainide 200–300 mg/day vs quinidine 1–1.5 g/day Method of AF cardioversion: pharmacological Warfarin discretionary
Outcomes	At 12 months: Mortality Proarrhythmia Adverse effects AF recurrence
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomisation not described.
Allocation concealment (selection bias)	Unclear risk	Procedure to conceal allocations not described.
Blinding (performance bias and detection bias) All outcomes	High risk	Open‐label study.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All withdrawals and dropouts were well described.
Selective reporting (reporting bias)	Low risk	All prespecified and expected outcomes of interest were well reported.
Other bias	Low risk	No other bias apparent.